Q3 business highlights at a glance

This podcast summary was generated with the assistance of AI tools based on the Q3/2025 earnings call transcript. While reviewed for accuracy, it may contain errors or interpretations not intended by Teva. For the official record, please refer to the full earnings call transcript.


You might also be interested

Teva Rise: Accelerating Pharma Innovation Globally

Teva employee using Augmented Reality solution

Building the Factory of the Future with Augmented Reality

3 Trends I’m Watching in Antibody Generation

Research, development, medicine

Shaping the Future of Medicine through Innovation & Collaboration

Chris fox, Eric Hughes

Innovation and Access: How Teva Is Developing the Next Generation of Medicine

3 Trends I’m watching in Pharma Manufacturing Modernization

Q2 business highlights at a glance

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Innovative medicine capsule with human and digital elements merging

The Future of Medicine is Now: 8 Ways Teva is Accelerating Healthcare Innovation Through AI, Advanced Devices, and Global Collaboration

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA